Published in Ther Adv Chronic Dis on September 01, 2011
The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females. Lipids Health Dis (2012) 1.01
Discriminant ratio and biometrical equivalence of measured vs. calculated apolipoprotein B100 in patients with T2DM. Cardiovasc Diabetol (2013) 0.80
TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity. Diabetes Metab Syndr Obes (2013) 0.79
The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population. PLoS One (2017) 0.77
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation (2005) 43.74
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet (2004) 42.12
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med (1998) 25.66
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 23.07
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med (2003) 20.06
Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med (2008) 18.27
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med (2005) 15.18
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet (2003) 13.69
Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75
The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) (2001) 8.45
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med (1990) 6.43
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med (2007) 6.31
High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet (2001) 6.31
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet (2010) 6.23
Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation (2002) 6.20
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol (2009) 5.65
Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation (1992) 4.96
Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation (1998) 4.39
Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation (2005) 3.85
Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care (2006) 3.37
Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation (2008) 3.23
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2008) 3.15
Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet (2008) 2.96
Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol (2008) 2.96
UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke (2002) 2.91
The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem (2001) 2.71
Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care (2003) 2.40
Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia (2006) 2.37
Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol (2008) 2.32
The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence. J Intern Med (2006) 2.29
Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation (2005) 2.21
Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Diabetes Care (2005) 2.07
New risk factors for atherosclerosis and patient risk assessment. Circulation (2004) 2.07
Novel HDL-directed pharmacotherapeutic strategies. Nat Rev Cardiol (2011) 1.91
Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care (2007) 1.91
Statin effects beyond lipid lowering--are they clinically relevant? Eur Heart J (2003) 1.90
The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med (2004) 1.89
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol (2008) 1.88
The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol (2005) 1.88
Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J Am Coll Cardiol (2008) 1.78
Prediction of first coronary events with the Framingham score: a systematic review. Am Heart J (2007) 1.74
Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol (2011) 1.71
Should triglycerides and the triglycerides to high-density lipoprotein cholesterol ratio be used as surrogates for insulin resistance? Metabolism (2009) 1.69
Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation (2010) 1.67
The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care (2006) 1.60
Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin (2010) 1.56
Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation (2000) 1.51
Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care (2004) 1.51
Usefulness of the triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort). Am J Cardiol (2008) 1.49
High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. Clinics (Sao Paulo) (2008) 1.45
Implications of emerging risk factors for therapeutic intervention. Nutr Metab Cardiovasc Dis (2005) 1.43
Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype B. Am J Cardiol (2004) 1.43
Normal triglyceride levels despite insulin resistance in African Americans: role of lipoprotein lipase. Metabolism (2005) 1.43
Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care (2004) 1.38
The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women's Ischemia Syndrome Evaluation (WISE). Am Heart J (2009) 1.36
log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males. Cardiovasc Diabetol (2010) 1.35
Future use of genomics in coronary artery disease. J Am Coll Cardiol (2007) 1.31
The physiological and molecular regulation of lipoprotein assembly and secretion. Mol Biosyst (2007) 1.30
Dietary carbohydrate restriction induces a unique metabolic state positively affecting atherogenic dyslipidemia, fatty acid partitioning, and metabolic syndrome. Prog Lipid Res (2008) 1.28
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res (2008) 1.27
Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis (2009) 1.25
Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins. Arterioscler Thromb Vasc Biol (2009) 1.23
A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol (2010) 1.22
Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol (2010) 1.22
Combination lipid therapy in type 2 diabetes. N Engl J Med (2010) 1.20
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther (2010) 1.18
Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study. Eur J Clin Invest (2007) 1.15
Redefining normal low-density lipoprotein cholesterol: a strategy to unseat coronary disease as the nation's leading killer. J Am Coll Cardiol (2010) 1.13
Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol (2010) 1.09
Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence. Cardiovasc Diabetol (2011) 1.09
Lifestyle approaches and dietary strategies to lower LDL-cholesterol and triglycerides and raise HDL-cholesterol. Endocrinol Metab Clin North Am (2009) 1.06
Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner is... Circulation (2005) 1.05
Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study. Eur J Cardiovasc Prev Rehabil (2007) 0.98
Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J (2006) 0.98
Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i). Curr Med Res Opin (2010) 0.97
HDL and triglyceride as therapeutic targets. Curr Opin Lipidol (2002) 0.96
Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study. Int J Obes (Lond) (2008) 0.96
Triglycerides: a risk factor for coronary heart disease. Atherosclerosis (1996) 0.94
Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol (2005) 0.93
Usefulness of triglycerides-to-high-density lipoprotein cholesterol ratio for predicting the first coronary event in men. Am J Cardiol (2009) 0.92
Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis (2010) 0.91
Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering. Am J Cardiol (2008) 0.91
Comparison of serum lipid values in subjects with and without the metabolic syndrome. Am J Cardiol (2008) 0.91
Weighing in before the fight: low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy. Circulation (2005) 0.89
Risk scores for prediction of coronary heart disease: an update. Endocrinol Metab Clin North Am (2009) 0.89
ApoB versus non-HDL-C: what to do when they disagree. Curr Atheroscler Rep (2009) 0.89
Molecular pathways and agents for lowering LDL-cholesterol in addition to statins. Pharmacol Ther (2010) 0.89
Erectile dysfunction, microangiopathy and UKPDS risk in type 2 diabetes. Diabetes Metab (2009) 0.87
Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels. Atherosclerosis (2000) 0.84
Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo. Pharmacol Ther (2009) 0.81
Management of non-high-density lipoprotein abnormalities. Atherosclerosis (2009) 0.81
Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD. Curr Cardiol Rev (2010) 0.81
Diabetes Care. Introduction. Diabetes Care (2010) 0.80
Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy. Am J Cardiol (2008) 0.80
Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates. Acta Cardiol (2008) 0.78
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med (2005) 15.18
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med (2007) 6.31
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet (2006) 5.67
Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest (2006) 3.48
Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care (2006) 3.37
The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem (2006) 2.38
Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes (2005) 2.32
Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res (2004) 2.16
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol (2006) 2.15
Increased ABCA1 activity protects against atherosclerosis. J Clin Invest (2002) 2.13
Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study. Atherosclerosis (2003) 2.02
C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol (2003) 1.99
Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation (2004) 1.98
The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem (2005) 1.85
Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest (2002) 1.80
Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta (2007) 1.79
Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci (2003) 1.78
The orphan nuclear receptor Rev-Erbalpha is a peroxisome proliferator-activated receptor (PPAR) gamma target gene and promotes PPARgamma-induced adipocyte differentiation. J Biol Chem (2003) 1.76
Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties. Circ Res (2004) 1.72
Identification of Rev-erbalpha as a physiological repressor of apoC-III gene transcription. J Lipid Res (2002) 1.71
PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol (2005) 1.68
Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element. Mol Endocrinol (2002) 1.63
Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes (2004) 1.63
Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORalpha. Arterioscler Thromb Vasc Biol (2005) 1.63
Atherogenic lipoprotein particles in atherosclerosis. Circulation (2004) 1.63
Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol (2003) 1.60
PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J Clin Invest (2005) 1.58
Perilipin, a potential substitute for adipophilin in triglyceride storage in human macrophages. Atherosclerosis (2006) 1.54
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology (2003) 1.54
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun (2004) 1.53
Adipophilin enhances lipid accumulation and prevents lipid efflux from THP-1 macrophages: potential role in atherogenesis. Arterioscler Thromb Vasc Biol (2004) 1.48
Implications of emerging risk factors for therapeutic intervention. Nutr Metab Cardiovasc Dis (2005) 1.43
Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis (2002) 1.41
Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab (2007) 1.41
Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest (2005) 1.37
Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem (2002) 1.36
Tissue-specific roles of ABCA1 influence susceptibility to atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.36
Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem (2003) 1.31
Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence. Arterioscler Thromb Vasc Biol (2006) 1.26
Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin (2004) 1.25
The role of PPARs in atherosclerosis. Trends Mol Med (2002) 1.22
Peroxisome proliferator-activated receptor alpha (PPARalpha ) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes. J Biol Chem (2002) 1.22
Transient impairment of the adaptive response to fasting in FXR-deficient mice. FEBS Lett (2005) 1.21
Both hepatic and extrahepatic ABCA1 have discrete and essential functions in the maintenance of plasma high-density lipoprotein cholesterol levels in vivo. Circulation (2006) 1.20
Combination lipid therapy in type 2 diabetes. N Engl J Med (2010) 1.20
Plasma cystatin-C and development of coronary heart disease: The PRIME Study. Atherosclerosis (2005) 1.19
Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arterioscler Thromb Vasc Biol (2004) 1.16
PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol (2006) 1.16
Transcriptional regulation of human Rev-erbalpha gene expression by the orphan nuclear receptor retinoic acid-related orphan receptor alpha. J Biol Chem (2002) 1.14
Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ Res (2006) 1.13
Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity. Mol Endocrinol (2008) 1.12
The nuclear receptor Rev-erbalpha is a liver X receptor (LXR) target gene driving a negative feedback loop on select LXR-induced pathways in human macrophages. Mol Endocrinol (2008) 1.11
FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology (2003) 1.11
PPARs: transcription factors controlling lipid and lipoprotein metabolism. Ann N Y Acad Sci (2002) 1.10
Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. Biochem Biophys Res Commun (2006) 1.09
Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol (2002) 1.09
DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha. Mol Endocrinol (2002) 1.07
The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha. Mol Endocrinol (2004) 1.07
Adipophilin increases triglyceride storage in human macrophages by stimulation of biosynthesis and inhibition of beta-oxidation. FEBS J (2006) 1.06
Apolipoprotein A-II, HDL metabolism and atherosclerosis. Atherosclerosis (2002) 1.06
The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem (2003) 1.05
Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages. Circ Res (2007) 1.05
The farnesoid X receptor induces very low density lipoprotein receptor gene expression. FEBS Lett (2004) 1.04
Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy. Curr Opin Pharmacol (2005) 1.03
Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor. Mol Cell Biol (2005) 1.02
Peroxisome proliferator-activated receptor alpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets. Diabetes (2006) 1.02
Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. Atherosclerosis (2004) 1.01
Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. J Biol Chem (2003) 1.00
Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins? Ann Med (2006) 0.99
Paullinia pinnata extracts rich in polyphenols promote vascular relaxation via endothelium-dependent mechanisms. J Cardiovasc Pharmacol (2006) 0.99
Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function. Curr Opin Lipidol (2003) 0.98
Hepatic expression of the UGT1A9 gene is governed by hepatocyte nuclear factor 4alpha. Mol Pharmacol (2004) 0.94
Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice. Arterioscler Thromb Vasc Biol (2004) 0.92
Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis. Expert Opin Emerg Drugs (2006) 0.92
The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-1c. J Biol Chem (2004) 0.92
Molecular mechanism of the blockade of plasma cholesteryl ester transfer protein by its physiological inhibitor apolipoprotein CI. J Biol Chem (2005) 0.92
The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol (2006) 0.92
The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis (2004) 0.91
[Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control]. J Soc Biol (2002) 0.91
Different ways to regulate the PPARalpha stability. Biochem Biophys Res Commun (2004) 0.91
FXR-deficiency confers increased susceptibility to torpor. FEBS Lett (2007) 0.91
Postprandial leptin response to carbohydrate and fat meals in obese women. J Am Coll Nutr (2003) 0.88
Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndrome. Clin Chem Lab Med (2007) 0.88
Genomic and non-genomic interactions of PPARalpha with xenobiotic-metabolizing enzymes. Trends Endocrinol Metab (2004) 0.88
Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia. Circ Res (2008) 0.87
Regulation of the scavenger receptor BI and the LDL receptor by activators of aldosterone production, angiotensin II and PMA, in the human NCI-H295R adrenocortical cell line. Biochim Biophys Acta (2003) 0.87
The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy. J Cardiovasc Pharmacol (2007) 0.87
Farnesoid X receptor represses hepatic lipase gene expression. J Lipid Res (2004) 0.87
Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes. Diabetologia (2005) 0.86
Potential regulatory role of the farnesoid X receptor in the metabolic syndrome. Biochimie (2005) 0.86
Extracellular human thioredoxin-1 inhibits lipopolysaccharide-induced interleukin-1beta expression in human monocyte-derived macrophages. J Biol Chem (2005) 0.85
Scavenger receptor BI (SR-BI) mediates a higher selective cholesteryl ester uptake from LpA-I compared with LpA-I:A-II lipoprotein particles. Atherosclerosis (2003) 0.85
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity. J Med Chem (2005) 0.85
Liver X receptor activation induces the uptake of cholesteryl esters from high density lipoproteins in primary human macrophages. Arterioscler Thromb Vasc Biol (2008) 0.83
Glucose regulates LXRalpha subcellular localization and function in rat pancreatic beta-cells. Cell Res (2006) 0.82
Daily melatonin supplementation in mice increases atherosclerosis in proximal aorta. Biochem Biophys Res Commun (2002) 0.82
Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia. Arch Med Res (2004) 0.82
Increased susceptibility of low-density lipoprotein to ex vivo oxidation in mice transgenic for human apolipoprotein B treated with 1 melatonin-related compound is not associated with atherosclerosis progression. J Cardiovasc Pharmacol (2005) 0.82
Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis. Trends Pharmacol Sci (2003) 0.82